Navigation Links
New Primer Co-Authored by Novation Describes Potential Impact of Biosimilars on Pharmacy Practice; Opportunity for Hospitals to Manage Drug Expenditures
Date:11/20/2013

IRVING, Texas, Nov. 20, 2013 /PRNewswire/ -- Health systems professionals should prepare now for the introduction of biosimilars, a new category of pharmaceuticals intended to offer lower cost alternatives for some of the most expensive medications purchased by health care organizations.  This insight comes from newly published research co-authored by Novation, the leading health care supply chain expertise, analytics and contracting company.

The primer, "Biosimilars: Implications for health-system pharmacists," appears in the Nov. 15 issue of the American Journal of Health-System Pharmacy (AJHP).  The peer-reviewed article provides an update on the scientific, regulatory, and clinical practice considerations that are continuing to shape the developing market of biosimilars in the United States. Unlike generic small molecules, biosimilars represent a greater level of complexity in design, manufacturing, and potential for immunogenicity.  As a result, they will require more robust clinical evaluation prior to formulary adoption.  Health care practitioners, particularly pharmacists, must take action now to enable their organizations to realize the full extent of value offered by these products.

According to lead author Steven Lucio, PharmD, BCPS, senior director, Clinical Solutions and Pharmacy Program Development, Novation, "While the development of biosimilars has been slow, we are rapidly approaching a point in time where these products no longer reside in only theoretical terms. Health-system pharmacists must recognize the unique molecular and manufacturing characteristics that differentiate small molecules from biologics and prepare to entertain clinical safety and efficacy discussions of biosimilars. Fortunately, we have the European experience with biosimilars to serve as an example."

Lucio added, "In addition, hospitals' existing familiarity with the sound principles of therapeutic interchange will enable them to support effective formulary management of this new class of pharmaceuticals."

The paper was co-authored by Jim Stevenson, chief pharmacy officer of the University of Michigan Health System and James Hoffman, medication outcomes and safety officer for St. Jude Children's Research Hospital. 

The primer can be downloaded by AJHP subscribers at www.ajhp.org.  For questions about this article, please contact Steven Lucio at slucio@novationco.com.

About Novation, Winner of the Ethics Inside® Certification

Founded in 1998, Novation is the leading health care supply chain expertise, analytics and contracting company for the more than 65,000 members and affiliates of VHA Inc. and UHC, two national health care alliances, Children's Hospital Association, an alliance of the nation's leading pediatric facilities, and Provista, LLC. Novation provides alliance members with sourcing services, as well as information and data services. Based in Irving, Texas, Novation develops and manages competitive contracts with more than 600 suppliers. VHA, UHC, and Provista members used Novation contracts to purchase approximately $43 billion in 2012. Novation earned the coveted Ethics Inside Certification from Ethisphere Institute, a leading international think tank dedicated to the research and promotion of best practices in corporate ethics and compliance. Novation was also named on Ethisphere's World's Most Ethical Companies list, and is the only company in the health care industry to earn both distinctions. To learn more about Novation, please visit www.novationco.com and follow @NovationNews.


'/>"/>
SOURCE Novation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. PrimeraDx Announces Commencement of Product Development Collaboration with Eli Lilly and Company
2. L.S.E. (Barcelona) anuncia la primera financiación del antiplaquetario NmC por inversores españoles y suizos
3. El Reino Unido, primer país europeo en ejecutar el programa Zostavax
4. PrimerLife.com, a Skolkovo Participant Company, Celebrates Anniversary of DNA Discovery with Launch of New Social Network
5. PrimerLife.com celebra el aniversario del descubrimiento del ADN con una nueva red social
6. Tras el exitoso lanzamiento en Estados Unidos, el nuevo Simbionix U/S Mentor se introducirá por primera vez en Europa
7. Ziehm Imaging: Primer brazo C motorizado para su uso en ORs híbridos
8. CryoLife anuncia el primer implante europeo del injerto HeRO
9. Aratana Therapeutics to Host Pet Therapeutics Primer and Product Update Event
10. Austen BioInnovation Institute in Akron Attracts Nationally Known Speakers For Conference on Value-driven Engineering, April 23-24
11. Netsmarts Focus on Innovation to Help Health and Human Service Providers Span the Spectrum of Care in the Healthcare 3.0 Environment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Eli Lilly and Company ... of its phase 3 EXPEDITION3 trial at the 9 ... As previously disclosed, solanezumab did not meet the primary ... solanezumab initiated in people with mild dementia due to ... submissions for solanezumab for the treatment of mild dementia ...
(Date:12/8/2016)... CITY , Dec. 8, 2016 ... US patents for improving the accuracy, reproducibility and ... images in long and small bone orthopaedic applications. ... approach to creating personalized orthopaedic restorations based on ... personalized orthopaedic restorations, the company harnesses the world,s ...
(Date:12/8/2016)... Mass. , Dec. 8, 2016  EIP ... it has obtained proof-of-mechanism for neflamapimod (previously code ... completed Phase 2a clinical trials that demonstrated significant ... Study 302 (12-week treatment) and Study 303 (6-week ... Clinical Trials in Alzheimer,s Disease (CTAD) scientific conference ...
Breaking Medicine Technology:
(Date:12/10/2016)... WASHINGTON, D.C. (PRWEB) , ... December 10, 2016 ... ... children’s Christmas wish lists for Santa are all sources of external stimuli that ... season. For some, the added pressure to spread holiday cheer through gifts, food ...
(Date:12/9/2016)... ... December 09, 2016 , ... ... aural rehabilitation—provided by audiologists—to remain a critical part of public access to hearing ... Administration (FDA) announced this week that, starting immediately, it would no ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Justin Veatch Fund ... (NCADD) is recommending the film Whispering Spirits and its discussion guide for ... as an education tool in the war against teen drug abuse. NCADD is ...
(Date:12/9/2016)... ... December 09, 2016 , ... MEDI+SIGN®, a provider of ... a new solution for Emergency Departments (ED) has been added to their portfolio. ... Department examination rooms, and with a simplified pallet of information available to the ...
(Date:12/8/2016)... ... 08, 2016 , ... After enjoying record-breaking attendance at its ... its 33rd Annual Issues & Research Conference, March 2-3, 2017, at the ... conference is “Persistent Challenges and New Opportunities: Using Research to Accelerate the Dialogue." ...
Breaking Medicine News(10 mins):